North America Viscosupplementation Market Size & Outlook
North America viscosupplementation market, 2018-2030 (US$M)
Related Markets
North America viscosupplementation market highlights
- The North America viscosupplementation market generated a revenue of USD 1,808.0 million in 2023.
- The market is expected to grow at a CAGR of 8.8% from 2024 to 2030.
- In terms of segment, single injection was the largest revenue generating product in 2023.
- Single Injection is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 1,808.0 million |
| Market revenue in 2030 | USD 3,255.1 million |
| Growth rate | 8.8% (CAGR from 2023 to 2030) |
| Largest segment | Single injection |
| Fastest growing segment | Single Injection |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Single Injection, Three Injection, Five Injection |
| Key market players worldwide | DePuy Synthes, Sanofi SA, Smith & Nephew PLC, Anika Therapeutics Inc, Zimmer Biomet Holdings Inc, Ferring, Lifecore Biomedical Inc, LG Chem, Roche Holding AG |
Other key industry trends
- In terms of revenue, North America region accounted for 37.5% of the global viscosupplementation market in 2023.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Europe is the fastest growing regional market and is projected to reach USD 1,284.7 million by 2030.
Single injection was the largest segment with a revenue share of 43.06% in 2023. Horizon Databook has segmented the North America viscosupplementation market based on single injection, three injection, five injection covering the revenue growth of each sub-segment from 2018 to 2030.
Growing preference for short treatment regimens, even though high priced, and growing prevalence of target diseases, such as osteoarthritis, are high impact rendering drivers that can be attributed for the large share of this region. In 2016, the most lucrative application of hyaluronic acid in the North American region was in the form of viscosupplements for management of osteoarthritis.
The most consistent growth is anticipated to be exhibited by single-injection cycle, as it offers convenience compared to its three-injection and five-injection counterparts. Growing demand for shorter regimen among population may drive the growth of single-injection cycles in the coming years.
According to Centers for Disease Control and Prevention (CDC), in 2015, the prevalence of doctor-diagnosed arthritis in the U.S. counties ranged from 11.2% to 42.7% in 3,142 counties in 50 states and District of Columbia. These factors are expected to consistently drive the North American market throughout the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Viscosupplementation Market Scope
Viscosupplementation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America viscosupplementation market size, by country, 2018-2030 (US$M)
North America Viscosupplementation Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
